Some aspects of the biology and endocrinology of prostate cancer

References

• Boyle P. The evolution of an epidemic of unknown origin, Denis. Eur Sch Oncol Monogr, Springer, HeidelbergGermany 1994; 5–11, in press
   Google Scholar
• Silverberg E, Boring C C, Squires T S. Cancer statistics. J Clin Cancer 1990; 40: 9–26
   Google Scholar
• Carter H B, Coffey D S. Prostate cancer: The magnitude of the problem in the United States. A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer, D S Coffey, M I Resnick, F A Dorr, et al. Plenum, New York, NY 1988; 1–7
   Google Scholar
• Sondik E. Incidence, survival and mortality trends in prostate cancer in the United States. A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer, D S Coffey, M I Resnick, F A Dorr, et al. Plenum, New York, NY 1988; 9–16
   Google Scholar
• World Health Organisation. WHO Weekly Epidemiological Record 1992; 67: 281–288
   PubMedGoogle Scholar
• Zaridze D G, Boyle P. Cancer of the prostate: Epidemiology and aetiology. Br J Urol 1987; 59: 493–503
   PubMedGoogle Scholar
• Schroeder F H, Boyle P. Screening for prostate cancer - Necessity or nonsense?. Eur J Cancer 1993; 29A: 656–661
   PubMedGoogle Scholar
• Boyle P, Alexander F E, Standaert B, et al. Screening for prostatic cancer. Rec Adv Urol 1994, in press
   Google Scholar
• Huggins C, Clark P J. Quantitative studies of prostatic secretion. II. The effect of castration and of estrogen injection on the normal and on the hyperplastic prostatic glands of dogs. J Exp Med 1940; 12: 741–162
   Google Scholar
• Huggins C, Hodges C V. Studies on prostatic cancer. The effect of castration, of estrogen and of androgen injection on semm phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–297
   Google Scholar
• Huggins C, Stevens R E, Hodges C V. Studies on prostatic cancer. II The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209–223
   Google Scholar
• Huggins C. Endocrine-induced regression of cancers, in Les Prix Nobel en 1966. Imprimerie Royale, P.a. Norstedt & Soner, StockholmGermany 1967; 172–182
   Google Scholar
• Weinberg R A. Oncogenes, antioncogenes and the molecular bases of multistep carcinogenesis. Cancer Res 1989; 49: 3713–3721
   PubMed Web of Science ®Google Scholar
• Sager R. Tumour suppressor genes: The puzzle and the promise. Science 1989; 246: 1406–1412
   PubMed Web of Science ®Google Scholar
• Seftel A D, Resnick M I. Rationale for surgical castration. Clinical Oncology: International Practice and Research, Prostatic Cancer, BJA Furr, L J Dennis. Balliere, LondonEngland 1988; 527–534
   Google Scholar
• Dodds E C, Goldberg L, Lawson W., et al. Oestrogenic activity of certain oestrogenic compounds. Nature (Lond) 1938; 141: 247–248
   Google Scholar
• Griffiths K, Davies P, Eaton C L, . Cancer of the prostate: Endocrine factors. Oxford Reviews of Reproductive Biology, J R Clark, et al. Oxford University, OxfordEngland 1988; vol 9: 192–259
   Google Scholar
• Griffiths K, Davies P, Eaton C L, . Endocrine factors in the initition, diagnosis and treatment of prostatic cancer. Endocrine Dependent Tumours, K D Voigt, C Knabbe, et al. Raven, New York, NY 1992; 83–130
   Google Scholar
• Resnick M I, Grayhack J T. Treatment of stage IV carcinoma of the prostate. Urol Clin North Am 1975; 2: 141–161
   PubMedGoogle Scholar
• Denis L J. Controversies in the management of localised and metastatic prostatic cancer. Eur J Cancer 1991; 27: 333–341
   PubMedGoogle Scholar
• Arduino L J. Veterans Administration Cooperative Research Group: Carcinoma of the prostate. Treatment and comparisons J Urol 1967; 98: 516–522
   Google Scholar
• Meilinger G T. Veterans Administration Cooperative Research Group: Carcinoma of the prostate: A continuing co-operative study. J Urol 1964; 91: 590–594
   PubMedGoogle Scholar
• Turkes A O, Peeling W B, Griffiths K. Treatment of patients with advanced cancer of the prostate: phase III tnal, Zoladex against castration. J Steroid Biochem 1987; 27: 543–549
   PubMedGoogle Scholar
• Kaisary A V, Ryan P G, Turkes A O, . A comparison between surgical orchidectomy and LH-RH analogue (‘Zoladex’, ICI 118630) in the treatment of advanced prostatic carcinoma-amulticentre clinical study. Management of Advanced Carcinoma of Prostate and Bladder, P M Smith, M Pavone-Macaluso, et al. Alan R. Liss Inc, New York, NY 1988; 89–100
   Google Scholar
• Auclair C, Kelly P A, Labrie F, et al. Inhibition of testicular LH/HCG receptor levels by treatment with a potent LH/RH agonist or HCG. Biochem Biophys Res Comm 1977; 76: 855–862
   PubMed Web of Science ®Google Scholar
• Schally A V, Coy D H, Meyers C A. Hypothalamic regulatory hormones. Ann Rev Biochem 1978; 47: 898–128
   Google Scholar
• Schally A V, Coman-Schally A M, Redding T W. Antitumour effects of analogues of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Exp Biol Med 1984; 175: 259–281
   PubMed Web of Science ®Google Scholar
• Corbin A. From contraception to cancer: A review of the therapeutic applications of LWRH analogues as antitumour agents. Yale J Biol Med 1982; 55: 27–47
   PubMed Web of Science ®Google Scholar
• Maynard P V, Nicholson R I. Effect of high doses of a series of new luteinizing hormone analogues in intact female rats. Br J Cancer 1979; 39: 274–279
   PubMedGoogle Scholar
• Nicholson R I, Walker K J, Maynard P V. Antitumour potential of a new luteinizing hormone releasing hormone analogue ICI 118630. Breast Cancer: Experimental and Clinical Aspects, H T Mourisden, T Palshof. Pergamon, New York, NY 1980; 296–299
   Google Scholar
• Labrie F, Dupont A, Belanger A. Spectacular response to combined antihormonal treatment in advanced prostate cancer. Endocrinology, F Labrie, L Proulz. Exerpta Medica, Quebec CityCanada 1984; 450–453, International Congress Series 655.
   Google Scholar
• Huggins C, Bergenstal D M. Effect of bilateral adrenalectomy on certain human tumours. Proc Natl Acad Sci USA 1952; 38: 73–76
   PubMedGoogle Scholar
• Harper M E, Peeling W B, Griffiths K. Adrenal androgens and the prostate. Hormonal Therapy of Prostatic Diseases: Basic and Clinical Aspects, M Motta, M Serio. Medicom Europe, Netherlands 1988; 81–104
   Google Scholar
• Geller J, Albert J D. Comparison of various hormone therapies for prostatic carcinoma. Semin Oncol 1983; 10: 34–42
   PubMedGoogle Scholar
• Labrie F, Dupont A, Belanger A. Complete androgen blockade for the treatment of prostate cancer. Important Advances in Urology, V T De Vita, S Hellman, S A Rosenberg. Lippincott, Philadelphia, PA 1985; 193–217
   Google Scholar
• Schulze H, Oesterling J E, Isaacs J T, . Hormonal therapy of prostate cancer: Limitations in the total androgen ablation concept. A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer, D S Coffey, M I Resnick, F A Dorr, et al. Plenum, New York, NY 1988; 9–16
   Google Scholar
• Schroeder F H. Total androgen suppression in the management of prostate cancer. Therapeutic Principles in Metastatic Prostate Cancer, B. Richards, F.H. Schroeder. Alan R. Liss, New York 1985; 307–319, A critical review, in EORTC Genitourinary Group Monograph 2, Part A.
   Google Scholar
• Denis W, Dalesio O, Murphy G P. Randomized trials on maximal androgen blockade in MI prostate cancer patients: An overview. 1994, in press
   Google Scholar
• Griffths K, Eaton C L, Harper M E, Turkes A O, Peeling W B. Hormonal Treatment of Advanced Disease: Some Newer Aspects. Semin Oncol 1994; 21: 672–687
   PubMedGoogle Scholar
• de Jong F H, Reuvers P J, Bolt-de Vries J, et al. Androgens and androgen receptors in prostate tissue from patients with benign prostatic hyperplasia: Effect of cyproterone acetate. J Steroid Biochem Molec Biol 1992; 42: 49–55
   PubMedGoogle Scholar
• Nicholson R I, Griffiths K. The biochemistry of tamoxifen action. Advances in Sex Hormone Research, J A Thomas, R L Singhal. Urban & Schwarzenberg, MunichGermany 1980; vol 4: 119–152
   Google Scholar
• Daniel C P, Gaskell S J, Bishop H, et al. Determination of tamoxifen and an hydroxylated metabolite in plasma from patients with advanced breast cancer using gas chromatography - mass spectrometry. J Endocrin 1979; 83: 401–408
   PubMed Web of Science ®Google Scholar
• Daniel C P, Gaskell S J, Bishop H, et al. Determination of tamoxifen and biologically active metabolites in human breast tumour and plasma. Eur J Cancer Clin Oncol 1981; 17: 1183–1189
   PubMedGoogle Scholar
• Wakeling A E, Furr BJA, Glen A T, et al. Receptor binding and biological activity of steroidal and nonsteroidal antiandrogens. J Steroid Biochem 1981; 15: 355–359
   PubMedGoogle Scholar
• Fawell S E, White R, Hoare S, et al. Inhibition of estrogen receptor-DNA binding by the ‘pure’ antiestrogen ICI 164384 appears to be mediated by impaired receptor dimerization. Roc Natl Acad Sci USA 1990; 87: 6883–6888
   PubMed Web of Science ®Google Scholar
• Akakura K, Bruchovsky N, Goldenberg S L, et al. Effects of intermittent androgen suppression on androgen-dependent turnours. Cancer 1993; 71: 2782–2790
   PubMed Web of Science ®Google Scholar
• Klotz L H, Herr H W, Morse M J, et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58: 46–50
   Google Scholar
• Bruchovsky N, Lesser B, Van Doom E, et al. Hormonal effects on cell proliferation in rat prostate. Vitamin Horm 1975; 33: 61–102
   PubMedGoogle Scholar
• Kyprianou N, Isaacs J T. Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: Critical threshold concept. Prostate 1987; 11: 41–50
   PubMed Web of Science ®Google Scholar
• Bruchovsky N, Brown E M, Coppin C M, . The endocrinology and treatment of prostate tumour progression. Current Concepts and Approaches to the Study of Prostate Cancer: Progression Clinical and Biological Research, D S Coffey, N Bruchovsky, W A Gardner, et al. Alan R. Liss, New York, NY 1987; 348–387
   Google Scholar
• Bruchovsky N, Rennie P S, Coldman A J., et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 2275–2282
   PubMed Web of Science ®Google Scholar
• Rennie P S, Bruchovsky N, Coldman A J. Loss of androgen dependence is associated with an increase in tumourigenic stem cells and resistance to cell-death genes. J Steroid Biochem Mol Biol 1990; 37: 843–847
   PubMedGoogle Scholar
• Truss M, Beato M. Steroid Hormone receptors: Interaction with deoxyribonucleic acid and transcription factors. Endocr Rev 1993; 14: 459–479
   PubMed Web of Science ®Google Scholar
• Griffiths K, Eaton C L, Harper M E, Weir AMK, Evans BAJ. Some Aspects of the Molecular Endocrinology of Prostatic Cancer: In ‘Antiandrogens’, L J Denis. Eur Sch Oncol Monogr. 1995, in press
   Google Scholar
• Petrovich M, Brand N J, Kmst A, et al. A human retinoic acid receptor that belongs to the family of nuclear receptors. Nature 1987; 330: 444–450
   PubMedGoogle Scholar
• Evans R M. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889–895
   PubMed Web of Science ®Google Scholar
• Schule R, Umesono K, Mangelsdorf D J, et al. Jun-fos and receptors for vitamins A and D recognise a common response element in the human osteocalcin gene. Cell 1990; 61: 497–504
   PubMed Web of Science ®Google Scholar
• Miller W H, May D, Li A, et al. Retinoic acid induces downregulation of several growth factors and proto-oncogenes in a human embryonal cancer cell line. Oncogene 1990; 5: 511–517
   PubMedGoogle Scholar
• Krust A, Kastner P, Petrovich M, et al. A third human retinoic acid receptor. Proc Natl Acad Sci 1989; 86: 5310–5314
   PubMed Web of Science ®Google Scholar
• Glass C K, Devary O V, Rosenfield M G. Multiple cell type specific proteins differentially regulate target sequence recognition by the a-retinoic acid receptor. Cell 1900; 63: 729–738
   Google Scholar
• Abb J, Deinhardt F. Retinoids inhibit the mitogenic activity of tumour promoting phorbol esters on human lymphocytes. Int J Cancer 1980; 25: 267–271
   PubMedGoogle Scholar
• McConnell J D, Wilson I D, George F W, et al. Finasteride, an inhibitor of Sa-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74: 505–508
   PubMed Web of Science ®Google Scholar
• Peeling W B, Abrams P H, Ramsay JWA, et al. Double-blind, placebo controlled study to evaluate the pharmacodynamic effects of SK & F 105657 in patients with benign prostatic hyperplasia. Proc 10th EAU Congress. GenoaItaly July, 1992
   Google Scholar
• McConnell J D, Akakura K, Bartsch G, et al. Hormonal treatment of BPH. Proc 2nd Int Consultation Benign Prostatic Hyperplasia. SCI, ParisFrance 1993; 418–436
   Google Scholar